GCK (glucokinase (hexokinase 4) ) Blocking Peptide (the N terminal of GCK)(100ug)

This is a synthetic peptide designed for use in combination with anti-GCK Antibody (ARP61473_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Prices direct from Aviva Systems Biology Incorporated

Quick response times

Exclusive Absave savings/discounts

SPECIFICATIONS

Size

100ug

Reactivities

Hum

Format

Lyophilized powder

Presku

AAP61473

Target

Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Alternative splicing of this gene results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in this gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), maturity onset diabetes of the young, type 2 (MODY2) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI).

Weight

51kDa

Gene Id

The peptide is characterized by mass spectroscopy

Alternative Names

FGQTL3; GK; GLK; HHF3; HK4; HKIV; HXKP; MODY2